DRMA / Dermata Therapeutics, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

As filed with the Securities and Exchange Commission on June 4, 2026

As filed with the Securities and Exchange Commission on June 4, 2026 Registration No.

NONQUALIFIED STOCK OPTION (INDUCEMENT) GRANT AGREEMENT DERMATA THERAPEUTICS, INC.

Exhibit 99.1 NONQUALIFIED STOCK OPTION (INDUCEMENT) GRANT AGREEMENT DERMATA THERAPEUTICS, INC. This Nonqualified Stock Option (Inducement) Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Dermata Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.0001 par value per share Other 244,471 $ 1.29 $ 315,367.59 0.0001381 $ 43.55 2 Equity Com

Dermata Therapeutics, Inc. Common Stock Preferred Stock Debt Securities Subscription Rights

Filed Pursuant to Rule 424(b)(3) Registration No. 333-291740 PROSPECTUS Dermata Therapeutics, Inc. $100,000,000 Common Stock Preferred Stock Warrants Debt Securities Subscription Rights Units We may offer, issue and sell from time to time together or separately, in one or more offerings, any combination of (i) our common stock, (ii) our preferred stock, which we may issue in one or more series, (i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commission

FOURTH AMENDMENT TO THE DERMATA THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN

Exhibit 10.1 FOURTH AMENDMENT TO THE DERMATA THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN This Fourth Amendment (the “Amendment”) to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”) of Dermata Therapeutics, Inc. (the “Company”), is made as of March 25, 2026. All capitalized terms used but not defined in this Amendment shall have the meanings assigned to such

As filed with the Securities and Exchange Commission on May 22, 2026

As filed with the Securities and Exchange Commission on May 22, 2026 Registration No.

Security Type

Calculation of Filing Fee Tables S-3 Dermata Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - Dermata announced their Tome Skincare brand for direct-to-consumer (“DTC”) skincare products - - Dermata plans to launch its first DTC product,

Exhibit 99.1 Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - Dermata announced their Tome Skincare brand for direct-to-consumer (“DTC”) skincare products - - Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 - - Raised $2.0 million in net proceed

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 March 31, 2026 DERMA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 March 31, 2026 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (I

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact Name of Regist

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 DERMATA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact Name of Regist

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

EXHIBIT 4.22 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the “Certificate of Incorporation”) and our amended and r

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 - Dermata announced a strategic pivot to develop and commercialize direct-to-consumer (“DTC”) skincare products under the brand name Tome - - Dermata

Exhibit 99.1 Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 - Dermata announced a strategic pivot to develop and commercialize direct-to-consumer (“DTC”) skincare products under the brand name Tome - - Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle of 2026 -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 DERMATA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 DERMATA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer

February 3, 2026

Exhibit 16.1 February 3, 2026 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Dermata Therapeutics, Inc. included under Item 4.01(a) of its Current Report on Form 8-K dated January 30, 2026, to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained the

1,484,312 Shares of Common Stock Up to 537,750 Shares of Common Stock Issuable Upon the Exercise of Outstanding Pre-Funded Warrants Up to 2,022,062 Shares of Common Stock Issuable Upon the Exercise of Outstanding Series C Warrants Up to 2,022,062 Sha

PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-292885 1,484,312 Shares of Common Stock Up to 537,750 Shares of Common Stock Issuable Upon the Exercise of Outstanding Pre-Funded Warrants Up to 2,022,062 Shares of Common Stock Issuable Upon the Exercise of Outstanding Series C Warrants Up to 2,022,062 Shares of Common Stock Issuable Upon the Exercise of Outstanding Series D Warrant

LETTER

January 26, 2026 Gerald T. Proehl Chief Executive Officer Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-3 Filed January 22, 2026 File No. 333-292885 Dear Gerald T. Proehl: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 r

THIS PAGE IS INTENTIONALLY LEFT BLANK IT IS NOT A PART OF EDGAR SUBMISSION

January 27, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2026 DERMATA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2026 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer

Up to $705,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268383 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated November 7, 2025, August 2, 2024, and June 7, 2024, to Prospectus dated November 25, 2022) Up to $705,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 25, 2022, filed as a part of our registration statement on Form S

Calculation of Filing Fee Tables Form S-3 (Form Type) Dermata Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dermata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on January 22, 2026

As filed with the Securities and Exchange Commission on January 22, 2026 Registration No.

SERIES [C]/[D] COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC.

Exhibit 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

PRE-FUNDED COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC.

Exhibit 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

[Signature Page Follows]

Exhibit 10.2 December 23, 2025 Holder of Warrants to Purchase Common Stock issued in January 2025 Re: Amendment to Existing Warrant Dear Holder: Reference is hereby made to the concurrent private placement offering on or about the date hereof (the “Offering”) by Dermata Therapeutics, Inc. (the “Company”) of its securities (collectively, the “Securities”). Capitalized terms used but not otherwise d

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 23, 2025, between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 23, 2025, by and between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Secur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2025 Dermata Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commi

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules $4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants

Exhibit 99.1 Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules $4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESSWIRE / December 24, 2025 / Dermata Therapeutics, Inc. (Nasdaq: DRMA)(Nasdaq: DRMAW) (“Dermata,” or the “Company”), a sci

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC.

Exhibit 4.3 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

DERMATA THERAPEUTICS. INC., as Issuer [●], as Trustee Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1

Exhibit 4.5 DERMATA THERAPEUTICS. INC., as Issuer and [●], as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between DERMATA THERAPEUTICS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b

DERMATA THERAPEUTICS, INC., as Issuer ●, as Trustee Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1

Exhibit 4.6 DERMATA THERAPEUTICS, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between DERMATA THERAPEUTICS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a)

As filed with the Securities and Exchange Commission on November 21, 2025

As filed with the Securities and Exchange Commission on November 21, 2025 Registration No.

Calculation of Filing Fee Table (Form Type) Dermata Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) Dermata Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commi

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC p

Exhibit 99.1 Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 - SAN DIEGO, CA, November 14, 2025 – Dermata Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2025 DERMATA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer

Up to $1,792,315 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268383 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated August 2, 2024, and June 7, 2024, to Prospectus dated November 25, 2022) Up to $1,792,315 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 25, 2022, filed as a part of our registration statement on Form S-3 (File No. 333

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2025 DERMATA THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2025 DERMATA THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 DERMATA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commiss

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial– - Raised $8.8 millio

Exhibit 99.1 Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial– - Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025 - SAN DIEGO, CA, August 13,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTICS, IN

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commissio

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., dated July 30, 2025.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DERMATA THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Dermata Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is Der

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commissio

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer of

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 DERMATA THERAPEUTICS, Inc.

Letter to Securities and Exchange Commission from Moss Adams LLP dated June 5, 2025.

Exhibit 16.1 June 5, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by the Dermata Therapeutics, Inc. included under Item 4.01 of its Current Report on Form 8-K dated June 3, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained therein. Sinc

ARS

81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :$6+,1*721'&  )250.

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 DERMATA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 DERMATA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer of

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTICS, I

March 31, 2025

Exhibit 99.1 Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints - - Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® f

10,007,352 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants

PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-286547 10,007,352 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale of up to 10,007,352 shares of Dermata Therapeutics, Inc. (the “Company,” “we,” “our” or “us”) common stock, par value $0.0001 per share, by the Selling Stockholders listed in this prospectus (the “Selling Stoc

THIS PAGE IS INTENTIONALLY LEFT BLANK IT IS NOT A PART OF EDGAR SUBMISSION

April 21, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.

LETTER

April 21, 2025 Gerald Proehl Chief Executive Officer Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-3 Filed April 15, 2025 File No. 333-286547 Dear Gerald Proehl: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding r

Dermata’s XYNGARI™ Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - Dermata previously announced XYNGARI™ produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional

EXHIBIT 99.1 Dermata’s XYNGARI™ Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - Dermata previously announced XYNGARI™ produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGARITM separated from placebo after just four once-weekly treatments - - XYNGARITM could be the first once

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dermata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on April 15, 2025

As filed with the Securities and Exchange Commission on April 15, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer o

Form of March 2025 New Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 28, 2025).

EXHIBIT 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Form of HCW Warrant

EXHIBIT 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

EXHIBIT 99.1 Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules SAN DIEGO, CA, March 27, 2025 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a de

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commissi

Form of Inducement Letter.

EXHIBIT 10.1 DERMATA THERAPEUTICS, INC. March 27, 2024 Holder of Warrants Issued in May 2024 and September 2024 Re: Inducement Offer to Exercise Warrants Issued in May 2024 and September 2024 Dear Holder: Dermata Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new warrants to purchase shares of the Company’s comm

BREAKING: Dermata’s XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints - XYNGARITM achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARITM is the first on

EXHIBIT 99.1 BREAKING: Dermata’s XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints - XYNGARITM achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARITM is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne - - Over 30 m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact Name of Regist

Insider Trading Policy.*

EXHIBIT 19.1 Adopted by the Board of Directors on March 4, 2025. DERMATA THERAPEUTICS, INC. INSIDER TRADING POLICY 1 INTRODUCTION As a public company, one of our important ethical duties is to protect and properly use nonpublic information acquired during our service with Dermata Therapeutics, Inc. (together with its subsidiaries, “Dermata” or the “Company”). This Insider Trading Policy (the “Poli

Exhibit 4.12

EXHIBIT 4.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the “Certificate of Incorporation”) and our amended and r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commissi

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results - Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 – - T

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results - Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 – - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laborator

1,935,412 Shares of Common Stock 72,468 Shares of Common Stock Issuable Upon the Exercise of Outstanding Pre-Funded Warrants 2,007,880 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants 140,552 Shares of Common Stock Iss

Filed Pursuant to Rule 424(b)(3) Registration No. 333-284603 PROSPECTUS 1,935,412 Shares of Common Stock 72,468 Shares of Common Stock Issuable Upon the Exercise of Outstanding Pre-Funded Warrants 2,007,880 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants 140,552 Shares of Common Stock Issuable Upon the Exercise of Outstanding Placement Agent Warrants This prospectu

February 3, 2025

CORRESP 1 filename1.htm February 3, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-284603 Acceleration Request Requested Date: February 5, 2025 Requested Time: 5:00 p.m., Eastern Time Dear Ladies and Gentlemen: Purs

LETTER

February 3, 2025 Gerald T. Proehl Chief Executive Officer Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-3 Filed January 30, 2025 File No. 333-284603 Dear Gerald T. Proehl: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 r

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dermata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on January 30, 2025

As filed with the Securities and Exchange Commission on January 30, 2025 Registration No.

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

EXHIBIT 99.2 Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / January 23, 2025 / Dermata Therapeutics, Inc. (Nasdaq: DRMA)(Nasdaq: DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the cl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commis

Form of January 2025 PIPE Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

EXHIBIT 4.3 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

EXHIBIT 99.1 Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / January 22, 2025 / Dermata Therapeutics, Inc. (Nasdaq: DRMA)(Nasdaq: DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has enter

Form of January 2025 PIPE Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

EXHIBIT 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Form of January 2025 PIPE Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 21, 2025, between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi

Form of January 2025 PIPE Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

EXHIBIT 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Form of January 2025 PIPE Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

EXHIBIT 10.2 EXHIBIT B REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 21, 2025, by and between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to

DERMATA AND REVANCE ENTER CLINICAL TRIAL COLLABORATION AGREEMENT FOR THE TOPICAL APPLICATION OF XYNGARI™ WITH DAXXIFY - The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyper

EXHIBIT 99.1 PRESS RELEASE DERMATA AND REVANCE ENTER CLINICAL TRIAL COLLABORATION AGREEMENT FOR THE TOPICAL APPLICATION OF XYNGARI™ WITH DAXXIFY - The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis - - If successful, the Companies may explore clinical development in additional indications - - Xyngari™ with Daxx

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commis

Clinical Trial Collaboration Agreement

EXHIBIT 10.1 CLINICAL TRIAL COLLABORATION AGREEMENT This CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of January 17, 2025 (the “Effective Date”) by and between Dermata Therapeutics, Inc., a Delaware corporation, located at 3525 Del Mar Heights Rd., #322, San Diego, CA 92130 (“Dermata”) and Revance Therapeutics, Inc. a Delaware corporation, having p

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commi

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussi

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 – S

DRMA / Dermata Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-drma093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Dermata Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 249845405 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTIC

5,871,587 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-282223 PROSPECTUS 5,871,587 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale of up to 5,871,587 shares of Dermata Therapeutics, Inc. (the “Company,” “we,” “our” or “us”) common stock, par value $0.0001 per share, by the Selling Stockholders listed in this prospectus (the “Selling Stockh

September 23, 2024

September 23, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.

LETTER

September 23, 2024 Kyri Van Hoose Chief Financial Officer Dermata Therapeutics, Inc.

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dermata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on September 19, 2024

As filed with the Securities and Exchange Commission on September 19, 2024 Registration No.

Form of September 2024 PIPE Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed with the SEC on September 17, 2024).

EXHIBIT 4.3 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Comm

Form of New Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the SEC on March 28, 2025).

EXHIBIT 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Form of Registration Rights Agreement

EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 16, 2024, by and between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Secu

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules Dermata raises approximately $7.8 million in gross proceeds since May 2024 – expected to fund its operations into the second quarter of 2

EXHIBIT 99.2 Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules Dermata raises approximately $7.8 million in gross proceeds since May 2024 – expected to fund its operations into the second quarter of 2025 SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq: DRMA)(Nasdaq: DRMAW) (“Dermata,” or the “Compan

Form of HCW Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the SEC on March 28, 2025).

EXHIBIT 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Form of September 2024 PIPE Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on September 17, 2024).

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 16, 2024, between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

EXHIBIT 99.1 Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / Dermata Therapeutics, Inc. (Nasdaq: DRMA)(Nasdaq: DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has ente

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commissi

As filed with the Securities and Exchange Commission on August 7, 2024

As filed with the Securities and Exchange Commission on August 7, 2024 Registration No.

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - - Dermata continues discussions with po

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - - Dermata continues discussions with potential botulinum toxin partners for DMT410 – - Raised $2.3 million in net proceeds from financing completed in 2Q 2024 - SAN DIEGO, CA,

Filing Fee Table

EXHIBIT 107.1 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Dermata Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of securities to be registered Fee Calculation Rule Amount to be registered(1) Proposed maximum offering price per share(2) Proposed maximum aggregate offering price(2) Fee Rate Amount of regist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTICS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction (Commission (IRS Employer o

Up to $505,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268383 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated June 7, 2024, to Prospectus dated November 25, 2022) Up to $505,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 25, 2022, filed as a part of our registration statement on Form S-3 (File No. 333-268383) (the “Registra

1,068,816 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants

Filed Pursuant to Rule 424b(3) Registration No. 333-280682 PROSPECTUS 1,068,816 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale of up to 1,068,816 shares of Dermata Therapeutics, Inc. (the “Company,” “we,” “our” or “us”) common stock, par value $0.0001 per share (the “Common Stock”), by the Selling Stockholders listed in this prospectus o

July10, 2024

CORRESP 1 filename1.htm July10, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-280682 Acceleration Request Requested Date: July 12, 2024 Requested Time: 4:15 p.m., Eastern Time Dear Ladies and Gentlemen: Pursuant to

LETTER

July 8, 2024 Gerald T. Proehl Chief Executive Officer Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-3 Filed July 3, 2024 File No. 333-280682 Dear Gerald T. Proehl: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding

As filed with the Securities and Exchange Commission on July 3, 2024

As filed with the Securities and Exchange Commission on July 3, 2024 Registration No.

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dermata Therapeutics, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commission

ATM Agreement, dated June 7, 2024, by and between Dermata Therapeutics, Inc. and H.C. Wainwright & Co., LLC.

EXHIBIT 1.1 AT THE MARKET OFFERING AGREEMENT June 7, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Dermata Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in th

Dermata Therapeutics, Inc. Up to $1,157,761 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268383 PROSPECTUS SUPPLEMENT (To Prospectus dated November 25, 2022) Dermata Therapeutics, Inc. Up to $1,157,761 Common Stock We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated June 7, 2024, relating to the sale of shares of our common stock, par value $0.0001

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commission

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commission

Form of Inducement Letter.

EXHIBIT 10.1 DERMATA THERAPEUTICS, INC. May 17, 2024 Holder of Warrants Issued in November 2023 and May 2023 Re: Inducement Offer to Exercise Warrants Issued in November 2023 and May 2023 Dear Holder: Dermata Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new warrants to purchase shares of the Company’s common s

Form of May 2024 New Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the SEC on May 17, 2024).

EXHIBIT 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

EXHIBIT 99.1 Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules SAN DIEGO, CA, May 17, 2024 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into def

Form of May 2024 Placement Agent Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the SEC on May 17, 2024).

EXHIBIT 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commission

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commission

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN DIEGO,

Amendment No. 3 of the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on May 14, 2024 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on May 14, 2024)

EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DERMATA THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Dermata Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is Der

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 DERMATA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commission

Amendment No. 3 to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on May 7, 2024). †

EXHIBIT 10.1 THIRD AMENDMENT TO THE DERMATA THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN This Third Amendment (the “Amendment”) to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”) of Dermata Therapeutics, Inc. (the “Company”), is made as of February 22, 2024. All capitalized terms used but not defined in this Amendment shall have the meanings assigned to such

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commission

ARS

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

ARS - PDF COPY

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results - Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 - - Raised $9.1 million in gross proceeds fro

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results - Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 - - Raised $9.1 million in gross proceeds from three financings completed in 2023 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN DIEGO,

Description of Securities.*

EXHIBIT 4.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the “Certificate of Incorporation”) and our amended and r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact Name of Regist

Clawback Policy of Dermata Therapeutics, Inc.*

EXHIBIT 97.1 DERMATA THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on September 26, 2023, and effective as of December 1, 2023) 1. Purpose Dermata Therapeutics, Inc. (the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has adopted th

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commissi

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

US2498453065 / DERMATA THERAPEUTICS INC / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G 1 armistice-drma123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Dermata Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 249845306 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commis

7,187,237 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333- 275931 PROSPECTUS 7,187,237 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale of up to 7,187,237 shares of Dermata Therapeutics, Inc. (the “Company,” “we,” “our” or “us”) common stock, par value $0.0001 per share (the “Common Stock”), by the Selling Stockholders listed in this prospectu

December 13, 2023

December 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.

LETTER

United States securities and exchange commission logo December 13, 2023 Gerald Proehl Chief Executive Officer Dermata Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the SEC Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dermata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on December 7, 2023

As filed with the Securities and Exchange Commission on December 7, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the SEC Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or other jurisdiction of incorporation) (Commi

Form of New Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 17, 2023).

EXHIBIT 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on November 17, 2023).

EXHIBIT 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Form of Inducement Letter (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 17, 2023).

EXHIBIT 10.1 DERMATA THERAPEUTICS, INC. November 16, 2023 Holder of Warrants Issued in March 2023 and April 2022 Re: Inducement Offer to Exercise Warrants Issued in March 2023 and April 2022 Dear Holder: Dermata Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new warrants to purchase shares of the Company’s commo

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

EXHIBIT 99.1 Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) (“Dermata” or the “Company”), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the entry into

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTIC

Regulation FD Disclosure, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commis

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback from FDA on its End of Pha

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 - - Completed start-up activities to support DMT310 Phase 3 STAR-1 clinical trial in acne - SAN DIEGO,

Filing Fee Table

EXHIBIT 107.1 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Dermata Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of securities to be registered Fee Calculation Rule Amount to be registered(1) Proposed maximum offering price per share(2) Proposedmaximum aggregate offering price(2) Fee Rate Amount of registr

As filed with the Securities and Exchange Commission on September 14, 2023

As filed with the Securities and Exchange Commission on September 14, 2023 Registration No.

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results - Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback on its End of Phase 2 mee

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results - Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 - - Phase 3 STAR-1 study is projected to start enrolling patients in the 2H 2023 - SAN DIEGO, CA, Augu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTICS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commissio

Amendment No. 2 to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 on Form 8-K filed with SEC on August 3, 2023).

EXHIBIT 10.1 SECOND AMENDMENT TO THE DERMATA THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN This Second Amendment (the “Amendment”) to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”) of Dermata Therapeutics, Inc. (the “Company”), is made as of June 4, 2023. All capitalized terms used but not defined in this Amendment shall have the meanings assigned to such te

Letter of Mayer Hoffman McCann P.C. to the Securities and Exchange Commission, dated August 3, 2023.

EXHIBIT 16.1 August 3, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Dermata Therapeutics, Inc.’s Form 8-K dated August 3, 2023, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4

856,938 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)4 Registration No. 333-273170 PROSPECTUS 856,938 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 856,938 shares of our common stock, par value $0.0001 per share (“Common Stock”), they

July 25, 2023

July 25, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.

LETTER

United States securities and exchange commission logo July 14, 2023 Gerald T. Proehl Chief Executive Officer Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-1 Filed July 7, 2023 File No. 333-273170 Dear Gerald T. Proehl: This is to advise you that we have not reviewed and will not review your registration

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

Filing Fee Table.*

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Dermata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on July 7, 2023

As filed with the Securities and Exchange Commission on July 7, 2023 Registration No.

ARS

ARS

Spongilla Spongilla Spongilla lacustris Spongilla Spongilla Spongilla Spongilla’s in- vitro Spongilla Spongilla Spongillav C.

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

DERMATA THERAPEUTICS, INC.

DERMATA THERAPEUTICS, INC. CONTROL ID: REQUEST ID: IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS DATE: THURSDAY, AUGUST 3, 2023 TIME: 9:00 A.M. PACIFIC TIME LOCATION: HTTPS://AGM.ISSUERDIRECT.COM/DRMA HOW TO REQUEST PAPER COPIES OF OUR MATERIALS PHONE: CALL TOLL FREE 1-866-752-8683 FAX: SEND THIS CARD TO 202-521-3464 INTERNET: HTTPS://WWW.IPR

US2498453065 / DERMATA THERAPEUTICS INC / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Dermata Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 249845306 (CUSIP Number) May 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

485,555 Shares of Common Stock Pre-Funded Warrants to Purchase up to 342,322 Shares of Common Stock 342,322 Shares of Common Stock Underlying the Pre-Funded Warrants

PROSPECTUS SUPPLEMENT (To Prospectus dated November 15, 2022) Filed Pursuant to Rule 424(b)(5) Registration No.

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 24, 2023).

EXHIBIT 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2023 Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commission

Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 24, 2023).

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 23, 2023, between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4. to the Company’s Current Report on Form 8-K filed on May 24, 2023).

EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

You’ve Exceeded the SEC’s Traffic Limit

EXHIBIT 99.1 Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules San Diego, CA/ ACCESSWIRE/ May 24, 2023/ Dermata Therapeutics, Inc. (“Dermata,” or the “Company”) (Nasdaq: DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into a definitive

Form of Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on May 24, 2023).

EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results - Dermata raised $5 million gross proceeds from a public offering in March 2023 – - Dermata submitted an End of Phase 2 meeting package to FDA in April 20

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results - Dermata raised $5 million gross proceeds from a public offering in March 2023 – - Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 – - FDA agreed that Dermata’s chemistry, manufacturing, and control (“CMC”) procedures support the initiation of Phase 3 studies of DM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-40739 DERMATA THERAPEUTICS, I

US2498453065 / DERMATA THERAPEUTICS INC / HALE DAVID F - SC 13D/A Activist Investment

SC 13D/A 1 drmasc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Dermata Therapeutics, Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 249845306 (CUSIP Number) Gerald T. Proehl President and Chief Executive Officer 3525 Del Mar Heights R

US2498453065 / DERMATA THERAPEUTICS INC / PROEHL GERALD T - FORM SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Dermata Therapeutics, Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 249845306 (CUSIP Number) Gerald T. Proehl President and Chief Executive Officer 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Teleph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Ex

Warrants to purchase up to 235,849 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-264668 Prospectus Supplement No. 3 Dated March 20, 2023 (To Prospectus Supplement Dated May 13, 2022) Warrants to purchase up to 235,849 Shares of Common Stock This Prospectus Supplement No. 3 (the “Supplement”) supplements the prospectus of Dermata Therapeutics, Inc. (the “Company”, “we”, “us”, or “our”) dated May 13, 2022 (as supple

85,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,533,123 Shares of Common Stock Series A Common Warrants to Purchase up to 1,618,123 Shares of Common Stock Series B Common Warrants to Purchase up to 1,618,123 Shares of Common Sto

Filed Pursuant to Rule 424(b)(4) Registration No. 333-270195 Prospectus 85,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,533,123 Shares of Common Stock Series A Common Warrants to Purchase up to 1,618,123 Shares of Common Stock Series B Common Warrants to Purchase up to 1,618,123 Shares of Common Stock Shares of Common Stock underlying Pre-Funded Warrants 1,618,123 Shares of C

Dermata Therapeutics Announces Closing of $5.0 Million Public Offering

EXHIBIT 99.2 Dermata Therapeutics Announces Closing of $5.0 Million Public Offering San Diego, CA/ ACCESSWIRE/ March 20, 2023/ Dermata Therapeutics, Inc. (“Dermata,” or the “Company”) (Nasdaq: DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously announced public offering of 1,618,123 s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 DERMATA THERAPEUTICS, INC. (Exact Name of registrant as Specified in its Charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of incorporation) (Commissi

Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering

EXHIBIT 99.1 Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering San Diego, CA/ ACCESSWIRE/ March 16, 2023/ Dermata Therapeutics, Inc. (“Dermata,” or the “Company”) (Nasdaq: DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the pricing of a public offering of 1,618,123 shares of the Company’s

As filed with the Securities and Exchange Commission March 16, 2023

As filed with the Securities and Exchange Commission March 16, 2023 Registration No.

Form of Series A and Series B Common Warrant issued in the March 2023 Offering (incorporated by reference to Exhibit 4.9 of the Company’s Registration Statement on Form S-1/A filed with the SEC on March 16, 2023).

U.S. Securities and Exchange Commission You’ve Exceeded the SEC’s Traffic Limit Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains

March 16, 2023

March 16, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

430 Park Avenue | New York, NY 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC

March 16, 2023 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-270195), as amended - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in

Filing Fee Table.*

EXHIBIT 107 EX-FILING FEES Calculation of Filing Fee Tables S-1 (Form Type) DERMATA THERAPEUTICS, INC.

Form of Purchase Agreement (incorporated by reference to Exhibit 10.23 to the Company’s Registration Statement on Form S-1/A (File No. 333-270195) filed on March 16, 2023).

EXHIBIT 10.23 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

As filed with the Securities and Exchange Commission March 15, 2023

As filed with the Securities and Exchange Commission March 15, 2023 Registration No.

430 Park Avenue | New York, NY 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC

March 14, 2023 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Dermata Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 (Registration No. 333-270195), as amended Withdrawal of Acceleration Request Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on March 13, 2023, in

March 14, 2023

March 14, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Amendment No. 2 of the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on March 13, 2023 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on March 13, 2023).

EXHIBIT 3.3 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DERMATA THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Dermata Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is Der

As filed with the Securities and Exchange Commission March 13, 2023

As filed with the Securities and Exchange Commission March 13, 2023 Registration No.

Form of Securities Purchase Agreement to be entered into in this Offering. *

EXHIBIT 10.23 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 DERMATA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commissi

VIA FACSIMILE AND EDGAR

March 13, 2023 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-270195), as amended - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in

Engagement Letter, dated as of November 27, 2022, by and between Dermata Therapeutics, Inc. and H.C. Wainwright & Co., LLC. **

EXHIBIT 1.1 November 27, 2022 STRICTLY CONFIDENTIAL Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Attn: Gerald T. Proehl, Chief Executive Officer Dear Mr. Proehl: This letter agreement (this “Agreement”) constitutes the agreement between Dermata Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclu

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.8 to the Company’s Registration Statement on Form S-1/A (File No. 333-270195) filed on March 13, 2023).

EXHIBIT 4.8 PREFUNDED COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2023 Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o

March 13, 2023

March 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Amendment No. 1 to the Engagement Letter, dated December 12, 2022, by and between Dermata Therapeutics, Inc. and H.C. Wainwright & Co., LLC. **

EXHIBIT 1.2 December 12, 2022 STRICTLY CONFIDENTIAL Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Attn: Gerald T. Proehl, Chief Executive Officer Dear Mr. Proehl: Reference is hereby made to that certain engagement agreement, dated as of November 27, 2022 (the “Agreement”), by and between Dermata Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wa

Form of Series A Common Warrant and Series B Common Warrant (incorporated by reference to Exhibit 4.9 to the Company’s Registration Statement on Form S-1/A (File No. 333-270195) filed on March 16, 2023).

EXHIBIT 4.9 COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2023 Initial Exercise Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set

Amendment No. 2 to the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., dated March 13, 2023. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report file on Form 8-K filed on March 13, 2023).

EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DERMATA THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Dermata Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is Der

Amendment No. 1 dated January 1, 2022 to the Employment Agreement by and between Dermata Therapeutics, Inc. and Kyri K. Van Hoose. (incorporated by reference to Exhibit 10.14 to the Company’s Registration Statement on Form S-1/A (File No. 333-270195) filed March 16, 2023).†

EXHIBIT 10.14 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (the “Amendment”) is made and entered into between Dermata Therapeutics, Inc. (the “Company”) and Kyri Van Hoose (the “Executive”) effective as of January 1, 2022 (the “Effective Date”). WHEREAS, Company and the Executive are parties to an Employment Agreement dated as of December 6, 2021 (the “Agree

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.10 to the Company’s Registration Statement on Form S-1/A (File No. 333-270195) filed on March 13, 2023).

EXHIBIT 4.10 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2023 Initial Exercise Date: , 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at

LETTER

United States securities and exchange commission logo March 6, 2023 Gerald T. Proehl President and Chief Executive Officer Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-1 Filed March 1, 2023 File No. 333-270195 Dear Gerald T. Proehl: This is to advise you that we have not reviewed and will not review yo

Filing Fee Table.**

EXHIBIT 107 EX-FILING FEES Calculation of Filing Fee Tables S-1 (Form Type) DERMATA THERAPEUTICS, INC.

Power of Attorney.**

As filed with the Securities and Exchange Commission March 1, 2023 Registration No.

Description of Securities.*

EXHIBIT 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the “Certificate of Incorporation”) and our amended and re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact Name of Regist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commi

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results - End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 – - Initiation of DMT310 Phase 3 clinical trial program in modera

EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results - End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 – - Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 - - DMT410 partnering discussions ongoing - SAN DIEGO, CA, February 21, 2023 – Dermata The

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40739 86-3218736 (State or Other Jurisdiction of Incorporation) (Commis

DRMA / Dermata Therapeutics, Inc. / PROEHL GERALD T - SC 13D/A Activist Investment

SC 13D/A 1 drmasc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Dermata Therapeutics, Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 249845108 (CUSIP Number) Gerald T. Proehl President and Chief Executive Officer 3525 Del Mar Heights R